

**NOTICE OF NEW HAMPSHIRE MEDICAID FEE FOR SERVICE  
DRUG UTILIZATION REVIEW BOARD  
PUBLIC HEARING  
December 8, 2023**

The New Hampshire Drug Utilization Review (DUR) Board invites you to attend a public hearing at 1:00 p.m., on December 8, 2023 in the Brown Building Conference Room 468 **and** via Zoom Conference. The DUR meeting will immediately follow this public hearing. The Zoom Conference information will be available 1 week prior to the DUR meeting at <https://nh.magellanrx.com/>.

The purpose of the public hearing is to solicit information and provide an opportunity for the public to present its views regarding the NH Medicaid Fee for Service pharmacy prior authorization criteria and PDL additions.

The public hearing will begin at 1:00 p.m. and end no later than 2:00 p.m. The DUR meeting will begin at or before 2:00 p.m., upon completion of public comments. The public is invited to present oral comments regarding the proposed prior authorization criteria and PDL additions. Members of the public shall notify the Department of Health and Human Services (DHHS) at least 48 hours in advance of the public hearing of their intent to comment at the public hearing. Comments will be limited to no longer than five (5) minutes per person and will be limited to the items on the agenda.

Written material may also be submitted by the public for DUR Board consideration, if received by DHHS at least 48 hours in advance of the meeting and may not exceed five (5) pages in length.

If accommodations are needed for communication access such as interpreters, CART (captioning), assistive listening devices, or other auxiliary aids and/or services, please contact Margaret 'Peg' Clifford at (603) 271-9098 by November 24, 2023. At least 5 business days advance notice is requested in order to assure availability; requests made fewer than 5 days prior to the event will attempt to be accommodated but cannot be guaranteed.

**DRUG UTILIZATION REVIEW BOARD MEETING  
December 8, 2023  
Meeting Agenda**

- I. Introductions and Welcome to Board Members
- II. Old Business
  - A. Minutes – 6/19/2023 review
- III. New Business
  - A. DUR Business Operations
    - 1. Overview of Drug Utilization Patterns for the New Hampshire Medicaid Fee-for Service Program
      - a. Prospective DUR Reports
      - b. Utilization Reports
      - c. Retrospective DUR Reports
  - B. COVID-19 Status Update

C. Review of Current Clinical Prior Authorization Criteria with Proposed Changes

1. Adenosine Triphosphate Citrate Lyase Inhibitor
2. Anti-Fungal Medication for Onychomycosis
3. Asthma/Allergy Immunomodulator
4. Calcitonin Gene-Related Peptide (CGRP) Inhibitor
5. Human Growth Hormones
6. Methadone (Pain Management Only)
7. Morphine Milligram Equivalent
8. Movement Disorders
9. Oral Isotretinoin
10. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
11. Pulmonary Arterial Hypertension
12. Spravato®
13. Synagis®
14. Systemic Immunomodulators
15. Vuity™

D. Review of Current Clinical Prior Authorization Criteria with No Proposed Changes

1. Brand Name Multiple Source Prescription Drug Product
2. Carisoprodol and Combination Medication
3. Hetlioz®/Hetlioz LQ™
4. Horizant®
5. New Drug Product
6. Psychoactive Medication for Children (5 Years of Age or Younger)
7. Psychotropic Medication Duplicate Therapy (Patients 6 Years and Older)
8. Second-Line Antifungal
9. Verquvo®

E. Proposal of Clinical Prior Authorization to Retire

1. Duloxetine
2. Pregabalin

F. Proposal of New Clinical Prior Authorization Criteria

1. Elevidys
2. GLP-1 Receptor Agonist
3. Roctavian™

IV. Adjourn

Further information regarding the agenda items may be obtained after November 24, 2023. Notice of intent to testify at the public hearing, and/or submittal of written comments, should be directed to Margaret 'Peg' Clifford, NH Department of Health and Human Services, 129 Pleasant Street, Concord, NH, 03301, (603) 271-9098, or e-mail at: [margaret.clifford@dhhs.nh.gov](mailto:margaret.clifford@dhhs.nh.gov).